Telomir Pharmaceuticals (TELO) Research & Development (2023 - 2026)
Telomir Pharmaceuticals' Research & Development was $444,674 in Q2 2026, up 938.0% from $42,839 a year earlier.
Powered by 
Analysis
Telomir Pharmaceuticals (TELO) Research & Development (2023 - 2026) Analysis & Trends
On a trailing twelve-month basis, Telomir Pharmaceuticals' Research & Development was $2.54 million through Jun 30, 2026, up 99.3% year-over-year; for FY2025, it was $2.44 million, up 9.0% from FY2024.
- Research & Development has now increased for three consecutive years, with a three-year compound annual growth rate of 43.0% (FY2022 to FY2025).
- In earlier years, Research & Development was $2.24 million in FY2024 (+42.0%), $1.57 million in FY2023 (+88.9%) and $833,206 in FY2022.
- Quarterly Research & Development has moved between $42,839 (Q2 2025) and $1.3 million (Q4 2025) over five years.
- Compared with a year earlier, Research & Development was higher in five of the last seven quarters, with growth averaging 194.4%.
- The best year-over-year quarter for Research & Development over five years was Q2 2026 (growth of 938.0%); the worst was Q2 2025 (a decline of 92.8%).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 655.56 Bn | 574.09 Bn | 17.26 Bn | 3.65 Bn |
| 2 | AbbVie | 470.94 Bn | 444.10 Bn | 12.70 Bn | 2.34 Bn |
| 3 | Merck | 367.14 Bn | 321.57 Bn | 12.21 Bn | 9.74 Bn |
| 4 | Novartis Ag | 280.33 Bn | 236.20 Bn | 11.24 Bn | -2.85 Bn |
| 5 | Astrazeneca | 257.78 Bn | 231.34 Bn | 12.86 Bn | -4.05 Bn |
| 6 | Amgen | 226.04 Bn | 181.44 Bn | 7.24 Bn | 1.87 Bn |
| 7 | Gilead Sciences | 188.89 Bn | 163.01 Bn | 6.22 Bn | 1.76 Bn |
| 8 | Pfizer | 163.75 Bn | 110.70 Bn | 10.94 Bn | 2.81 Bn |
| 9 | Vertex Pharmaceuticals | 133.68 Bn | 105.69 Bn | 2.84 Bn | 993.80 Mn |
| 10 | Telomir Pharmaceuticals | 82.53 Mn | 82.53 Mn | - | 444,674.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 444,674.00 |
| Dec 31, 2025 | 1.30 Mn |
| Sep 30, 2025 | 759,525.00 |
| Jun 30, 2025 | 42,839.00 |
| Mar 31, 2025 | 336,996.00 |
| Dec 31, 2024 | 269,083.00 |
| Sep 30, 2024 | 627,434.00 |
| Jun 30, 2024 | 594,801.00 |
| Mar 31, 2024 | 804,023.00 |
| Dec 31, 2023 | 203,784.00 |
| Sep 30, 2023 | 262,562.00 |
| Jun 30, 2023 | 667,626.00 |
| Mar 31, 2023 | 440,335.00 |
API Access
Telomir Pharmaceuticals Research & Development API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=research-and-development&ticker=TELO&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "research-and-development", "ticker": "TELO", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=research-and-development&ticker=TELO&period=max&api_key=YOUR_API_KEY");
const data = await res.json();